by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Bio Technology : July 2009
AusBioSTOCK SPOTLIGHT PHOSPHAGENICS LTD (ASX:POH] $0.14 Listed August 1993 Market Capitalisation $93 M Month H $0.17 – L $0.13 (vol 9 m ) Issued Capital 663.5m OFP shares 5 m options Cash March 31st December 2008 Aus $ 10 m Principal Activity Pharmaceutical and nutraceutical company with a diversified portfolio of technologies, focused on the development and commercialisation of its patented phosphorylation technologies and products. PHARMACEUTICAL: Transdermal delivery technology, TPM-01 and TPM-02, are the most advanced projects in Phosphagenics' development pipeline. The first drug to enter clinical trials using the TPM-01 technology is a transdermal morphine formulation, and for TPM-02 a transdermal insulin formulation. As at December 2008, POH successfully completed a phase 1 clinical trial that examined the ability of TPM drug delivery system to topically deliver the pain relief drug, lidocaine, safely into humans. Additionally the company received ethics approval to commence treating patients with Type 1 diabetes in a phase 2 clinical trial using its patented transdermal insulin delivery system, TPM/insulin. NUTRACEUTICALS: Developing products such as dietary supplements (vitamin capsules & tablets), personal care-skin care products and functional foods (nutritionally enhanced foods). The first commercial product is Phospha E, a novel patented derivative of vitamin E, is available as a dietary supplement (Ester-E)-in the US, Canada and Indonesia. Current research includes coenzyme Q10, retinol and omega-3 fatty acids. ASX Announcements Successful Completion of a Phase 1 Clinical Trial using TPM/ Oxycodone. Data demonstrates that repeat applications of TPM/oxycodone formulation does not cause significant opioid induced erythema or sensitisation significant erythema or sensitisation in humans. 19 June 2009 Signs research and option agreement with global specialty biopharmaceutical company, CSL to evaluate TPM technology. The early stage research collaboration will focus on evaluating Phosphagenics’ proprietary TPM delivery technology to deliver large proteins. Pursuant to the collaborative arrangement, Phosphagenics will develop new formulations containing its patented TPM delivery system in combination with a number of CSL’s protein based formulations. 29 May 2009 Completion of Transdermal Patch Prototypes − Oxycodone Successfully Delivered into the Bloodstream − Data Demonstrates Sustained Release and Increased Blood Levels of Oxycodone 38 Australasian BioTechnology Volume 19 • Number 2 • July 2009 by Joanna Hill 30 April 2009 Retinoic Acid Trial Demonstrates Increased Delivery and Reduced Irritation. Trial confirms Phosphagenics’ TPM platform technology and demonstrates markedly increased delivery of retinoic acid with reduced irritation compared to a leading commercial product. 23 February 2009 Completion of its Phase 1 diclofenac study, which demonstrated that its patented TPM/diclofenac formulation was safe and well tolerated in humans. The results also indicate that Phosphagenics’ formulation can deliver significant amounts of diclofenac deep into the area of application. Diclofenac is one of the leading products of a class of drugs known as NSAIDs (non steroid anti-inflammatory drugs) with global sales exceeding US $1.2 billion. It is used to reduce nflammation and pain associated with inflammation of tendons or joins (tendonitis or arthritis) and acute injuries. 1 Year 5 Years